tirzepatide vs insulin Mounjaro vs. Insulin: Which Is More Effective for Type 2 Diabetes? Tirzepatide stands apart by targeting

safer is unproven

Additional Resources Semaglutide Clinical Trial New England Journal of Medicine Tirzepatide Clinical Trial New England Journal of Medicine Medically authored by Dr

This success story has already spawned further studies investigating the next generation of incretin drugs, including triple receptor agonists and oral peptide therapies

After one year of treatment, the average weight loss with tirzepatide was 17.2 kg (about 38 pounds), representing 16.5% of body weight

Your healthcare provider can review your medication regimen, assess for potential drug interactions, check blood pressure and blood glucose levels, and evaluate for other causes of dizziness unrelated to Mounjaro

SURMOUNT-2: Confirmed weight loss and metabolic benefit in people with diabetes In adults with obesity or overweight with Type 2 diabetes, tirzepatide met co-primary endpoints, showing superior weight loss versus placebo at 72 weeks, with meaningful reductions in weight, high percentages achieving 5% weight loss, and improvements in glycaemic and metabolic outcomes